The hepatitis C virus (HCV) is a plus-stranded RNA virus that infects more than 100 million people and causes acute and chronic hepatitis and hepatocellular carcinoma. The outcome of HCV infection is thought to be determined by the high replication and mutation rates of the virus, and by the kinetics, magnitude, quality and duration of the T cell response. In particular, many HCV-specific CD8( T cells that can be visualized with HLA class I tetramers fail to produce inteferon gamma (IFNgamma), especially during chronic infection. The potential importance of this dysfunctional phenotype in the pathogenesis of HCV infection is suggested by our recent observations that: (a) it also heralds the onset of the CD8( T cell response to HCV during the incubation phase of infection; (b) it correlates with high viral titers and significant liver cell injury during acute viral hepatitis; (c) it recovers or is replaced by CD8+ T cells that produce IFNgamma when the virus is cleared. We suggest that dynamic changes in T cell function such as this, and others that have not yet been examined, may have an important impact on the course and outcome of HCV infection. In the current application, therefore, we will test this hypothesis by comparing the phenotypic and functional evolution of the CD4( and CD8( T cell responses to HCV with the severity and duration of infection in acutely and chronically infected humans and chimpanzees. We will also perform in vivo depletion experiments to directly examine whether CD4+ or CD8+ T cells control HCV infection, and to determine the extent to which their antiviral potential is mediated by IFNgamma. This information will not only provide fundamental insight into the immunobiology of HCV infection, it may also lead to the development of immunotherapeutic and antiviral approaches to prevent and treat this serious disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA076403-10
Application #
7246669
Study Section
Experimental Virology Study Section (EVR)
Program Officer
Read-Connole, Elizabeth Lee
Project Start
1997-12-12
Project End
2008-11-30
Budget Start
2007-06-01
Budget End
2008-11-30
Support Year
10
Fiscal Year
2007
Total Cost
$542,558
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Wieland, S F; Asabe, S; Engle, R E et al. (2014) Limited hepatitis B virus replication space in the chronically hepatitis C virus-infected liver. J Virol 88:5184-8
Asabe, Shinichi; Wieland, Stefan F; Chattopadhyay, Pratip K et al. (2009) The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 83:9652-62
Sidney, John; Peters, Bjoern; Moore, Carrie et al. (2007) Characterization of the peptide-binding specificity of the chimpanzee class I alleles A 0301 and A 0401 using a combinatorial peptide library. Immunogenetics 59:745-51
Sakai, Akito; Takikawa, Shingo; Thimme, Robert et al. (2007) In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells. J Virol 81:7208-19
Sidney, John; Asabe, Shinichi; Peters, Bjoern et al. (2006) Detailed characterization of the peptide binding specificity of five common Patr class I MHC molecules. Immunogenetics 58:559-70
Guidotti, Luca G; Chisari, Francis V (2006) Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1:23-61
Neumann-Haefelin, C; Blum, H E; Chisari, F V et al. (2005) T cell response in hepatitis C virus infection. J Clin Virol 32:75-85
Kapadia, Sharookh B; Chisari, Francis V (2005) Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 102:2561-6
Wieland, Stefan F; Chisari, Francis V (2005) Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 79:9369-80
Wieland, Stefan; Thimme, Robert; Purcell, Robert H et al. (2004) Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 101:6669-74

Showing the most recent 10 out of 14 publications